论文部分内容阅读
目的 :观察中西医结合治疗肺癌患者的白细胞介素 2 (IL 2 )系统、T细胞及红细胞免疫系统动态改变与临床评估。方法 :随机将肺癌患者分为两组 :Ⅰ组 (化疗加中药 ) 2 5例 ,Ⅱ组 (化疗 ) 2 3例。动态观察治疗前后免疫指标及生存质量、临床证候与瘤体改变。且以健康人为对照。结果 :(1)肺癌患者血清IL 2与可溶性白细胞介素 2受体 (sIL 2R)分别显著低于与高于对照组。治疗后上述指标分别显著回升和下降。尤以Ⅰ组改善为著。但仍与对照组有显著差异 ;且两组肺癌患者IL 2与sIL 2R之间呈高度负相关。 (2 )两组肺癌患者CD3、CD4 、CD4 /CD8均显著低下。而CD8则显著高于对照组 ;红细胞免疫指标红细胞C3b受体花环 (RBC C3bRR)、红细胞免疫复合物花环 (RBC ICR)分别显著低于与高于对照组 ;治疗后均有所改善 ,呈相对应负性改变 ,也以Ⅰ组明显。CD4 /CD8则较治疗前有显著改善 ,但除CD8外 ,余均仍显著低于对照 ;进而分别显示CD4 /CD8比值与RBC C3bRR间呈高度正相关。 (3)生存质量、临床证候和实体瘤改变等方面评估均为Ⅰ组优于Ⅱ组。结论 :中西医结合治疗肺癌对于改善生存质量、临床证候和实体瘤改变取得了较好的疗效 ,尤其对于中晚期肺癌。
Objective: To observe the dynamic changes and clinical assessment of interleukin 2 (IL 2) system, T cell and erythrocyte immune system in patients with lung cancer treated with integrated traditional Chinese and western medicine. Methods: Patients with lung cancer were randomly divided into two groups: group Ⅰ (chemotherapy plus traditional Chinese medicine) 25 cases, group Ⅱ (chemotherapy) 23 cases. Dynamic observation of immune indicators before and after treatment and quality of life, clinical syndromes and tumor changes. And healthy people as a control. Results: (1) Serum IL 2 and soluble interleukin 2 receptor (sIL 2R) in patients with lung cancer were significantly lower than those in the control group. After treatment, the above indicators were significantly increased and decreased. Especially in group Ⅰ improvement. But still significant difference with the control group; and there was a highly negative correlation between IL-2 and sIL 2R in two groups of lung cancer patients. (2) CD3, CD4, CD4 / CD8 of lung cancer patients in both groups were significantly lower. While the level of CD8 in the control group was significantly higher than that in the control group. The levels of erythrocyte erythrocyte C3b receptor rosette (RBC C3bRR) and erythrocyte immune complex rosette (RBC ICR) were significantly lower and higher than those in the control group Corresponding to the negative changes, but also to group Ⅰ obvious. CD4 / CD8 was significantly improved compared with that before treatment, except for CD8, the remaining were significantly lower than the control; and then showed a high degree of positive correlation between CD4 / CD8 ratio and RBC C3bRR. (3) Quality of life, clinical syndromes and changes in solid tumors were evaluated as group Ⅰ superior to group Ⅱ. Conclusion: Integrative treatment of lung cancer for improving quality of life, clinical syndromes and solid tumors have achieved good results, especially for advanced lung cancer.